We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-10.34%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.07B
AUM Growth
-$1.75B
Cap. Flow
-$1.68B
Cap. Flow %
-157.42%
Top 10 Hldgs %
79.25%
Holding
36
New
4
Increased
1
Reduced
17
Closed
11

Top Buys

Rank Stock Value
1
ICLR icon
Icon
ICLR
+$42.6M
2
MRK icon
Merck
MRK
+$39.7M
3
UNH icon
UnitedHealth
UNH
+$38.2M
4
APLS
Apellis Pharmaceuticals
APLS
+$15.7M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.89M

Top Sells

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$121M
2
HUM icon
Humana
HUM
+$106M
3
BAX icon
Baxter International
BAX
+$87.9M
4
CVS icon
CVS Health
CVS
+$78.7M
5
PTCT icon
PTC Therapeutics
PTCT
+$76.4M

Sector Composition

Rank Sector Weight
1 Healthcare 67.39%

No holdings matched the selected filter criteria.

1 2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Camber Capital Management held 36 positions worth $1.07B, down 62% from $2.81B the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Camber Capital Management withdrew a net $1.68B in Q2 2025, closing 11 positions and reducing 17 holdings. Its most notable exit was PTC Therapeutics, an estimated $76.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 57% a quarter earlier.

Against the trend, Camber Capital Management opened a new position in Icon worth $43.6M.

  • Camber Capital Management's largest Q2 2025 buy was Icon: 300,000 shares worth $43.6M.
  • Camber Capital Management added most to BioMarin Pharmaceuticals in Q2 2025, an estimated $5.89M increase.
  • Camber Capital Management's biggest Q2 2025 reduction was Zimmer Biomet, cutting an estimated $121M.
  • Camber Capital Management fully exited PTC Therapeutics in Q2 2025, selling an estimated $76.4M.
  • Camber Capital Management's ten largest holdings make up 79% of its $1.07B portfolio in Q2 2025.
  • Camber Capital Management opened 4 new positions and closed 11 in Q2 2025.
  • Camber Capital Management's portfolio value fell 62% quarter-over-quarter to $1.07B.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.